Skip to main content
. 2019 Feb 13;9(3):455–468. doi: 10.1016/j.apsb.2019.02.002

Figure 5.

Fig. 5

(A) Representative coronal SPECT/CT images of W256 tumor-bearing rats obtained at 4 h post injection of 131I-vitexin. W256 tumor-bearing rats were pretreated with 20 mg/kg combretastatin A-4 disodium phosphate (CA4P) or were left untreated (Control) for 24 h. White arrows indicate significantly different uptakes of the tracer in the tumors of model and control rats. (B) Autoradiographs, corresponding H&E staining images and micrographs of 10 μm tumor slices from model and control rats administered with 131I-vitexin. (Adapted with permission from Ref. 74. Copyright © 2018 American Chemical Society).